Our article on SPECT/CT published on July 7, 2005 incorrectly stated that Boston Life Sciences had submitted and was awaiting approval for a new drug application (NDA) to the Food and Drug Administration for its I-123 Altropane radiopharmaceutical.
Although the company completed a phase III trial for Altropane, it has not yet submitted an NDA. It is now conducting a second phase III trial under a special protocol assessment (SPA) with the FDA to determine the agent's potential use in differentiating Parkinsonian from non-Parkinsonian tremors.
In addition, it was incorrectly stated that a match in nuclear ventilation/perfusion (V/Q) scan is considered suspicious of a pulmonary embolism. This should have read that a mismatch is considered suspicious of PE.
You can read the corrected article by clicking here.
